Roundtable Discussion:Navigating FDA Regulatory Pathways to Accelerate Liquid Biopsy Approval & Adoption
Time: 3:30 pm
day: Conference Day 2
Details:
- What are the key FDA regulatory requirements for liquid biopsy assays, and how do they differ for companion diagnostics versus standalone tests?
- How can developers navigate the evolving FDA landscape, including the impact of recent LDT regulations on liquid biopsy commercialization?
- What strategies can companies use to engage with the FDA early, streamline approval pathways, and ensure compliance while maintaining innovation?
